Epstein‑Barr Virus Early Antigen D Antibody (IgG)
Also known as: EBV Early Antigen Diffuse Antibody, EBV EA-D Antibody
Use
IgG antibodies recognizing the Epstein‑Barr Virus Early Antigen D (EA‑D) typically emerge during acute infection—usually within a month of clinical presentation—and are transient, lasting approximately 3–4 months. Persistently elevated EA‑D IgG levels may suggest EBV reactivation or ongoing infection, including possible lymphoproliferative disorders.
Special Instructions
Not provided.
Limitations
This immunoassay detects diffuse (D) EA‑D IgG and does not differentiate between restricted (R) and diffuse (D) forms. IgG EA‑D levels may remain elevated for years in a minority of individuals. False‑negative results may occur in immunosuppressed patients. It should not be used as a standalone diagnostic; interpret results together with clinical evaluation and other EBV serologic markers (e.g., VCA, EBNA).
Methodology
Immunoassay (Other)
Biomarkers
Epstein‑Barr Virus Early Antigen D Antibody (IgG)
Analyte
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red Top (No Additive)
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 4 Days |
| Refrigerated | 7 Days |
| Frozen | 30 Days |
Other tests from different labs that may be relevant